
Neurogene Inc.: shareholders and insiders
Price
$22.15
November 20, 2026Market cap $613M
What Ploutos Investor adds for Neurogene
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Oct 2, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$1.1M
4 people
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $1.1M by 4 people
- 2025: no buys, no sales
- 2026: no buys, sold $1.1M by 4 people
- Sep 22, 2026Rachel McMinnChief Executive OfficerKind
- Jul 7, 2026Christine Mikail CvijicPresident and CFOKind10b5-1
- Jul 6, 2026Christine Mikail CvijicPresident and CFOKind10b5-1
- Jul 2, 2026Christine Mikail CvijicPresident and CFOKind10b5-1
- Jul 2, 2026Christine Mikail CvijicPresident and CFOKind10b5-1
- Jul 1, 2026Christine Mikail CvijicPresident and CFOKind10b5-1
- May 6, 2026Christine Mikail CvijicPresident and CFOKind10b5-1
- May 6, 2026Christine Mikail CvijicPresident and CFOKind10b5-1
- Mar 26, 2026Christine Mikail CvijicPresident and CFOKind10b5-1
- Mar 26, 2026Rachel McMinnChief Executive OfficerKind10b5-1
- Mar 26, 2026Julie JordanChief Medical OfficerKind10b5-1
- Mar 13, 2026Christine Mikail CvijicPresident and CFOKind10b5-1
- Mar 13, 2026Christine Mikail CvijicPresident and CFOKind10b5-1
- Mar 13, 2026Christine Mikail CvijicPresident and CFOKind10b5-1
- Mar 13, 2026Stuart CobbChief Scientific OfficerKind10b5-1
- Mar 13, 2026Stuart CobbChief Scientific OfficerKind10b5-1
- Mar 13, 2026Stuart CobbChief Scientific OfficerKind10b5-1
- Feb 27, 2026Christine Mikail CvijicPresident and CFOKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | Rachel McMinnChief Executive Officer | 756 | $25.32 | $19.1K | Form 4 | |
| Jul 7, 2026 | Christine Mikail CvijicPresident and CFO | 10b5-1 | 4,200 | $36.13 | $151.8K | Form 4 |
| Jul 6, 2026 | Christine Mikail CvijicPresident and CFO | 10b5-1 | 600 | $36.02 | $21.6K | Form 4 |
| Jul 2, 2026 | Christine Mikail CvijicPresident and CFO | 10b5-1 | 2,531 | $34.58 | $87.5K | Form 4 |
| Jul 2, 2026 | Christine Mikail CvijicPresident and CFO | 10b5-1 | 1,530 | $35.23 | $53.9K | Form 4 |
| Jul 1, 2026 | Christine Mikail CvijicPresident and CFO | 10b5-1 | 739 | $34.06 | $25.2K | Form 4 |
| May 6, 2026 | Christine Mikail CvijicPresident and CFO | 10b5-1 | 4,800 | $30.07 | $144.3K | Form 4 |
| May 6, 2026 | Christine Mikail CvijicPresident and CFO | 10b5-1 | 4,800 | $32.44 | $155.7K | Form 4 |
| Mar 26, 2026 | Christine Mikail CvijicPresident and CFO | 10b5-1 | 2,558 | $21.62 | $55.3K | Form 4 |
| Mar 26, 2026 | Rachel McMinnChief Executive Officer | 10b5-1 | 3,352 | $22.07 | $74.0K | Form 4 |
| Mar 26, 2026 | Julie JordanChief Medical Officer | 10b5-1 | 828 | $21.89 | $18.1K | Form 4 |
| Mar 13, 2026 | Christine Mikail CvijicPresident and CFO | 10b5-1 | 2,387 | $20.42 | $48.7K | Form 4 |
| Mar 13, 2026 | Christine Mikail CvijicPresident and CFO | 10b5-1 | 1,395 | $21.25 | $29.6K | Form 4 |
| Mar 13, 2026 | Christine Mikail CvijicPresident and CFO | 10b5-1 | 263 | $22.02 | $5.8K | Form 4 |
| Mar 13, 2026 | Stuart CobbChief Scientific Officer | 10b5-1 | 148 | $22.08 | $3.3K | Form 4 |
| Mar 13, 2026 | Stuart CobbChief Scientific Officer | 10b5-1 | 3,991 | $20.41 | $81.5K | Form 4 |
| Mar 13, 2026 | Stuart CobbChief Scientific Officer | 10b5-1 | 2,658 | $21.34 | $56.7K | Form 4 |
| Feb 27, 2026 | Christine Mikail CvijicPresident and CFO | 10b5-1 | 4,800 | $25.11 | $120.5K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jul 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by NGNE's officers and directors from 2014 up to November 21, 2025, 12 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 7 more, back to 2014
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Prudential FinancialCommonShare of class11.2%
- Jennison Associates LLCShare of class11.1%
- RTW Investments, LPwith 1 more personShare of class9.99%
- EcoR1 Capital, LLCwith 2 more personsShare of class9.90%
- Redmile Group, LLCwith 2 more personsShare of class9.90%
- Casdin Capital, LLCwith 3 more personsShare of class8.70%
- Baker Bros. Advisors LPwith 3 more personsShare of class7.00%
- BlackRock, Inc.Share of class6.80%
- Balyasny Asset Managementwith 4 more personsShare of class5.18%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Prudential FinancialCommon | 11.2% | 2.23M | Oct 7, 2026 | 13G | |
| Jennison Associates LLC | 11.1% | 2.23M | Oct 6, 2026 | 13G | |
| RTW Investments, LPwith 1 more person | 9.99% | 1.50M | Feb 14, 2025 | 13G/A | |
| EcoR1 Capital, LLCwith 2 more persons | 9.90% | 1.44M | Nov 14, 2025 | 13G/A | |
| Redmile Group, LLCwith 2 more persons | 9.90% | 1.57M | Aug 14, 20263 filings since Feb 14, 2025 | 13G/A | |
| Casdin Capital, LLCwith 3 more persons | 8.70% | 1.30M | Feb 14, 2025 | 13G/A | |
| Baker Bros. Advisors LPwith 3 more persons | 7.00% | 991.8K | Aug 14, 20252 filings since May 15, 2025 | 13G/A | |
| BlackRock, Inc. | 6.80% | 1.01M | Apr 23, 2025 | 13G/A | |
| Balyasny Asset Managementwith 4 more persons | 5.18% | 818.7K | Aug 14, 2026 | 13G |
Fell to 5% or less (5)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter+68%
- Citadel Advisors (Griffin)In the quarter-77%
- Millennium Mgmt (Englander)In the quarter-42%
- D.E. ShawIn the quarter
- Renaissance TechnologiesIn the quarter-50%
- AQR CapitalIn the quarter+0.8%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 239.0K | +68% | $6.6M | 0.01% |
| Citadel Advisors (Griffin) | 92.9K | -77% | $2.6M | 0.00% |
| Millennium Mgmt (Englander) | 24.6K | -42% | $700.0K | 0.00% |
| D.E. Shaw | – | – | 0.00% | |
| Renaissance Technologies | 10.2K | -50% | $300.0K | 0.00% |
| AQR Capital | 15.2K | +0.8% | $400.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 18.4% of its shares outstanding were held short, +2.4% since the report before.
- Shares held short
- 5.09M
- 18.4%
- Since the report before4.97M on Sep 30, 2026
- +2.4%
- 14.4
- 354.7K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 98%
- Report date
- Oct 15, 2026
- Shares held short
- Dec 29, 2023: Shares held short 7,254
- Jan 12, 2024: Shares held short 18.9K
- Jan 31, 2024: Shares held short 39.2K
- Feb 15, 2024: Shares held short 155.0K
- Feb 29, 2024: Shares held short 260.6K
- Mar 15, 2024: Shares held short 393.2K
- Mar 28, 2024: Shares held short 906.0K
- Apr 15, 2024: Shares held short 988.1K
- Apr 30, 2024: Shares held short 1.02M
- May 15, 2024: Shares held short 997.8K
- May 31, 2024: Shares held short 977.4K
- Jun 14, 2024: Shares held short 1.06M
- Jun 28, 2024: Shares held short 1.07M
- Jul 15, 2024: Shares held short 1.44M
- Jul 31, 2024: Shares held short 1.56M
- Aug 15, 2024: Shares held short 1.74M
- Aug 30, 2024: Shares held short 1.82M
- Sep 13, 2024: Shares held short 1.79M
- Sep 30, 2024: Shares held short 1.90M
- Oct 15, 2024: Shares held short 934.6K
- Oct 31, 2024: Shares held short 914.2K
- Nov 15, 2024: Shares held short 1.64M
- Nov 29, 2024: Shares held short 1.17M
- Dec 13, 2024: Shares held short 1.60M
- Dec 31, 2024: Shares held short 1.82M
- Jan 15, 2025: Shares held short 1.82M
- Jan 31, 2025: Shares held short 2.01M
- Feb 14, 2025: Shares held short 1.75M
- Feb 28, 2025: Shares held short 1.96M
- Mar 14, 2025: Shares held short 2.18M
- Mar 31, 2025: Shares held short 2.44M
- Apr 15, 2025: Shares held short 2.86M
- Apr 30, 2025: Shares held short 2.95M
- May 15, 2025: Shares held short 2.70M
- May 30, 2025: Shares held short 2.39M
- Jun 13, 2025: Shares held short 2.25M
- Jun 30, 2025: Shares held short 2.21M
- Jul 15, 2025: Shares held short 2.55M
- Jul 31, 2025: Shares held short 2.59M
- Aug 15, 2025: Shares held short 2.66M
- Aug 29, 2025: Shares held short 2.74M
- Sep 15, 2025: Shares held short 2.82M
- Sep 30, 2025: Shares held short 2.84M
- Oct 15, 2025: Shares held short 2.86M
- Oct 31, 2025: Shares held short 2.84M
- Nov 14, 2025: Shares held short 3.32M
- Nov 28, 2025: Shares held short 3.29M
- Dec 15, 2025: Shares held short 3.54M
- Dec 31, 2025: Shares held short 3.50M
- Jan 15, 2026: Shares held short 3.54M
- Jan 30, 2026: Shares held short 3.59M
- Feb 13, 2026: Shares held short 3.61M
- Feb 27, 2026: Shares held short 3.67M
- Mar 13, 2026: Shares held short 3.89M
- Mar 31, 2026: Shares held short 4.03M
- Apr 15, 2026: Shares held short 4.01M
- Apr 30, 2026: Shares held short 3.72M
- May 15, 2026: Shares held short 3.60M
- May 29, 2026: Shares held short 3.55M
- Jun 15, 2026: Shares held short 3.55M
- Jun 30, 2026: Shares held short 3.35M
- Jul 15, 2026: Shares held short 2.93M
- Jul 31, 2026: Shares held short 3.01M
- Aug 14, 2026: Shares held short 3.04M
- Aug 31, 2026: Shares held short 3.14M
- Sep 15, 2026: Shares held short 3.28M
- Sep 30, 2026: Shares held short 4.97M
- Oct 15, 2026: Shares held short 5.09M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading59.5% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 59.5% of the shares in the reported trades were short sales, against 72.7% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 59.5%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 72.7%
- Change
- -13.2 pts
- Short sales a dayon average, of 105.0K shares
- 62.5K
- More than atof 3,666 US-listed companies, same days
- 81%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 77.4%
- Oct 15, 2026: Short sales 83.4%
- Oct 16, 2026: Short sales 79.1%
- Oct 19, 2026: Short sales 45.6%
- Oct 20, 2026: Short sales 72.7%
- Oct 21, 2026: Short sales 88.3%
- Oct 22, 2026: Short sales 46.9%
- Oct 23, 2026: Short sales 56.1%
- Oct 26, 2026: Short sales 51.7%
- Oct 27, 2026: Short sales 80.8%
- Oct 28, 2026: Short sales 61.4%
- Oct 29, 2026: Short sales 52%
- Oct 30, 2026: Short sales 72.8%
- Nov 2, 2026: Short sales 64.4%
- Nov 3, 2026: Short sales 66.7%
- Nov 4, 2026: Short sales 78.9%
- Nov 5, 2026: Short sales 35.7%
- Nov 6, 2026: Short sales 55.9%
- Nov 9, 2026: Short sales 57.9%
- Nov 10, 2026: Short sales 83.2%
- Nov 11, 2026: Short sales 84.3%
- Nov 12, 2026: Short sales 38.1%
- Nov 13, 2026: Short sales 63.9%
- Nov 16, 2026: Short sales 43.3%
- Nov 17, 2026: Short sales 47.4%
- Nov 18, 2026: Short sales 62.3%
- Nov 19, 2026: Short sales 61.5%
- Nov 20, 2026: Short sales 70.2%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Srinivas AkkarajuTenPercentOwnerDirectly–
- Rachel McMinnChief Executive OfficerDirectly1.35M
- Christine Mikail CvijicPresident and CFODirectly84.0K
- Stuart CobbChief Scientific OfficerDirectly30.5K
- Julie JordanChief Medical OfficerDirectly12.5K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Srinivas AkkarajuTenPercentOwner | – | 1.69M | Nov 26, 2024 | Form 4 |
| Rachel McMinnChief Executive Officer | 1.35M | – | Sep 22, 2026 | Form 4 |
| Christine Mikail CvijicPresident and CFO | 84.0K | – | Jul 7, 2026 | Form 4 |
| Stuart CobbChief Scientific Officer | 30.5K | – | Mar 13, 2026 | Form 4 |
| Julie JordanChief Medical Officer | 12.5K | – | Mar 26, 2026 | Form 4 |
A lower bound: it counts only the 5 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.08%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.05%
- IBBiShares Biotechnology ETFWeight in the fund0.03%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.02%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VHTVanguard Health Care Index FundWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.00%
- IWViShares Russell 3000 ETFWeight in the fund0.00%
13 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 88
- Q4 2025: Managers 93
- Q1 2026: Managers 97
- Q2 2026: Managers 112
Institutional investors by quarter
The fund managers holding NGNE, quarter by quarter, from Q4 2023 to Q2 2025, 7 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 11 quarters.
Q2 2026: 112 managers held 17.31M shares, worth $544M. During the quarter 22 opened a position, 7 closed one, 35 added and 31 trimmed.
The largest holders, Q2 2026
- Samsara BiocapitalIn the quarter
- Casdin CapitalIn the quarter+8.8%
- Redmile GroupIn the quarter-3.2%
- Rtw InvestmentsIn the quarter
- EcoR1 CapitalIn the quarter
- BlackRockIn the quarter+5.3%
- Baker Bros. AdvisorsIn the quarter
- Balyasny Asset ManagementIn the quarter+14%
- Trails Edge Capital PartnersIn the quarter-8.7%
- Toronto Dominion BankIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Samsara Biocapital | 1.72M | $54M | |
| Casdin Capital | 1.55M | +8.8% | $49M |
| Redmile Group | 1.41M | -3.2% | $44M |
| Rtw Investments | 1.36M | $43M | |
| EcoR1 Capital | 1.27M | $40M | |
| BlackRock | 1.06M | +5.3% | $33M |
| Baker Bros. Advisors | 991.7K | $31M | |
| Balyasny Asset Management | 818.7K | +14% | $26M |
| Trails Edge Capital Partners | 714.9K | -8.7% | $22M |
| Toronto Dominion Bank | 681.3K | $21M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Neurogene's filings show?
Who buys and sells is one part of Neurogene's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have NGNE's insiders bought or sold?
From Jul 2, 2026 to Oct 2, 2026 Neurogene's insiders bought 0 and sold $340.0K of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold NGNE?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Point72 (Cohen)'s, worth $6.6M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.